.

Deeper Knowledge, Faster

  • Predict branded drug patent expiration
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Chubb
Healthtrust
Cantor Fitzgerald
Farmers Insurance
QuintilesIMS
Harvard Business School
Fuji
Accenture
Fish and Richardson
Queensland Health

Generated: June 26, 2017

DrugPatentWatch Database Preview

RESTORIL Drug Profile

« Back to Dashboard

Which patents cover Restoril, and when can generic versions of Restoril launch?

Restoril is a drug marketed by Mallinckrodt Inc and is included in one NDA.

The generic ingredient in RESTORIL is temazepam. There are seven drug master file entries for this compound. Thirty-eight suppliers are listed for this compound. Additional details are available on the temazepam profile page.

Summary for Tradename: RESTORIL

Patents:0
Applicants:1
NDAs:1
Suppliers / Packagers: see list4
Bulk Api Vendors: see list16
Clinical Trials: see list1
Patent Applications: see list3,891
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:RESTORIL at DailyMed

Pharmacology for Tradename: RESTORIL

Ingredient-typeBenzodiazepines
Drug ClassBenzodiazepine
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mallinckrodt Inc
RESTORIL
temazepam
CAPSULE;ORAL018163-003Oct 25, 1991ABRXYesNo► Subscribe► Subscribe
Mallinckrodt Inc
RESTORIL
temazepam
CAPSULE;ORAL018163-002Approved Prior to Jan 1, 1982ABRXYesYes► Subscribe► Subscribe
Mallinckrodt Inc
RESTORIL
temazepam
CAPSULE;ORAL018163-001Approved Prior to Jan 1, 1982ABRXYesNo► Subscribe► Subscribe
Mallinckrodt Inc
RESTORIL
temazepam
CAPSULE;ORAL018163-004Nov 2, 2004ABRXYesNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: RESTORIL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Mallinckrodt Inc
RESTORIL
temazepam
CAPSULE;ORAL018163-003Oct 25, 19915,030,632► Subscribe
Mallinckrodt Inc
RESTORIL
temazepam
CAPSULE;ORAL018163-003Oct 25, 19915,326,758► Subscribe
Mallinckrodt Inc
RESTORIL
temazepam
CAPSULE;ORAL018163-003Oct 25, 19915,211,954► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

US Department of Justice
Harvard Business School
Fuji
Teva
Cerilliant
Baxter
Farmers Insurance
Moodys
Daiichi Sankyo
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot